English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAn experimental therapeutic monoclonal antibody therapy could become the first to directly enhance tissue repair in the heart following a heart attack.
Tag: Monoclonal Antibody
NEJM: Results From Targeted Therapy for Ulcerative Colitis Study
An international placebo-controlled study led by Cedars-Sinai suggests that a targeted drug therapy that was developed by researchers at Cedars-Sinai is safe and effective at helping people with moderate to severe ulcerative colitis reach clinical remission.
How Effective Is MS Medication Across Racial and Ethnic Groups?
For people with relapsing-remitting multiple sclerosis (MS), a new study has found that the drug ofatumumab is more effective than teriflunomide at helping people across racial and ethnic groups reach a period of no disease activity. The study is published in the July 17, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Small Study Shows Promise for Antimalarial Monoclonal Antibody to Prevent Malaria
monoclonal antibody treatment was found to be safe, well tolerated, and effective in protecting against malaria in a small group of healthy volunteers who were exposed to malaria in a challenge study, according to new research published in The Lancet Infectious Diseases by researchers at the University of Maryland School of Medicine (UMSOM).
UPMC and Pitt Share Insights on Operationalizing Outpatient COVID-19 Monoclonal Antibody Treatment
As evidence mounts supporting the use of monoclonal antibody treatment to reduce hospitalizations and deaths from COVID-19, UPMC and University of Pittsburgh School of Medicine physician-scientists are sharing the health system’s experience administering the life-saving medication.
COVID-19: Monoclonal Antibody Drugs Available for High-Risk Patients
UVA Health is offering monoclonal antibody drugs for appropriate patients with COVID-19 who are at highest risk for developing severe symptoms and requiring hospitalization.
Rapid Method Finds Potent COVID-19 Monoclonal Antibody Among a Trillion Possibilities
University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. The method – as well as a trio of successful animal studies on an antibody called “Ab1” – are described today in the Proceedings of the National Academy of Sciences. Ab1 is on track for human clinical trials by early next year.
NEJM: Clinical Trial Indicates Monoclonal Antibody Lowered Hospitalizations and Emergency Visits
COVID-19 (coronavirus) patients who were administered a novel antibody had fewer symptoms and were less likely to require hospitalization or emergency medical care than those who did not receive the antibody, according to a new study published in the The New England Journal of Medicine.
Preclinical testing of inhaled monoclonal antibody for COVID-19 shows therapeutic efficacy
An inhaled monoclonal antibody treatment against the SARS-CoV-2 virus may lead to self-administered therapy for COVID-19, according to preclinical tests. It was discovered at UAB and the Texas Biomedical Research Institute, and it has been licensed for development to Aridis Pharmaceuticals.
First Patients in NIH ACTIV-3 Clinical Trial Enroll in Dallas
On Wednesday in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.